nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A4—chronic obstructive pulmonary disease	0.237	0.373	CbGaD
Duloxetine—CYP1A2—chronic obstructive pulmonary disease	0.216	0.34	CbGaD
Duloxetine—HTR2A—chronic obstructive pulmonary disease	0.182	0.287	CbGaD
Duloxetine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0337	0.263	CbGbCtD
Duloxetine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0327	0.255	CbGbCtD
Duloxetine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0327	0.255	CbGbCtD
Duloxetine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0291	0.227	CbGbCtD
Duloxetine—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00851	0.415	CbGeAlD
Duloxetine—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00309	0.151	CbGeAlD
Duloxetine—NPY1R—lung—chronic obstructive pulmonary disease	0.00135	0.066	CbGeAlD
Duloxetine—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.00107	0.0523	CbGeAlD
Duloxetine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.000982	0.0479	CbGeAlD
Duloxetine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000864	0.0422	CbGeAlD
Duloxetine—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000664	0.0324	CbGeAlD
Duloxetine—Protriptyline—SLC6A4—chronic obstructive pulmonary disease	0.000641	0.162	CrCbGaD
Duloxetine—Cinacalcet—CYP1A2—chronic obstructive pulmonary disease	0.000624	0.158	CrCbGaD
Duloxetine—SLC6A3—lung—chronic obstructive pulmonary disease	0.000569	0.0278	CbGeAlD
Duloxetine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000521	0.0254	CbGeAlD
Duloxetine—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.00052	0.0254	CbGeAlD
Duloxetine—SLC6A2—lung—chronic obstructive pulmonary disease	0.000459	0.0224	CbGeAlD
Duloxetine—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000457	0.0223	CbGeAlD
Duloxetine—Fluoxetine—SLC6A4—chronic obstructive pulmonary disease	0.000438	0.111	CrCbGaD
Duloxetine—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000418	0.0204	CbGeAlD
Duloxetine—Fluoxetine—CYP1A2—chronic obstructive pulmonary disease	0.000398	0.101	CrCbGaD
Duloxetine—HTR2A—trachea—chronic obstructive pulmonary disease	0.000384	0.0187	CbGeAlD
Duloxetine—CYP1A2—lung—chronic obstructive pulmonary disease	0.000353	0.0172	CbGeAlD
Duloxetine—Fluoxetine—HTR2A—chronic obstructive pulmonary disease	0.000336	0.0851	CrCbGaD
Duloxetine—Propranolol—ADRB2—chronic obstructive pulmonary disease	0.000294	0.0744	CrCbGaD
Duloxetine—Atomoxetine—SLC6A4—chronic obstructive pulmonary disease	0.000281	0.0711	CrCbGaD
Duloxetine—HTR2A—lung—chronic obstructive pulmonary disease	0.000276	0.0135	CbGeAlD
Duloxetine—Propranolol—CYP1A1—chronic obstructive pulmonary disease	0.000252	0.0638	CrCbGaD
Duloxetine—Propranolol—CYP1A2—chronic obstructive pulmonary disease	0.000243	0.0615	CrCbGaD
Duloxetine—Fluoxetine—ALB—chronic obstructive pulmonary disease	0.00023	0.0582	CrCbGaD
Duloxetine—Atomoxetine—HTR2A—chronic obstructive pulmonary disease	0.000216	0.0546	CrCbGaD
Duloxetine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000155	0.00089	CcSEcCtD
Duloxetine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000155	0.00089	CcSEcCtD
Duloxetine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.000887	CcSEcCtD
Duloxetine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000155	0.000887	CcSEcCtD
Duloxetine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.000884	CcSEcCtD
Duloxetine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000154	0.000884	CcSEcCtD
Duloxetine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000154	0.000883	CcSEcCtD
Duloxetine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000154	0.000883	CcSEcCtD
Duloxetine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.000883	CcSEcCtD
Duloxetine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000154	0.00088	CcSEcCtD
Duloxetine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.000875	CcSEcCtD
Duloxetine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000152	0.000873	CcSEcCtD
Duloxetine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000152	0.000871	CcSEcCtD
Duloxetine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000151	0.000865	CcSEcCtD
Duloxetine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000858	CcSEcCtD
Duloxetine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000858	CcSEcCtD
Duloxetine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.000852	CcSEcCtD
Duloxetine—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.000849	CcSEcCtD
Duloxetine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000147	0.000845	CcSEcCtD
Duloxetine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.000844	CcSEcCtD
Duloxetine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000843	CcSEcCtD
Duloxetine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.000841	CcSEcCtD
Duloxetine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000146	0.000837	CcSEcCtD
Duloxetine—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000146	0.000837	CcSEcCtD
Duloxetine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.000833	CcSEcCtD
Duloxetine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000145	0.00083	CcSEcCtD
Duloxetine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.00083	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000145	0.000828	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000145	0.000828	CcSEcCtD
Duloxetine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000143	0.000822	CcSEcCtD
Duloxetine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000143	0.000822	CcSEcCtD
Duloxetine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000143	0.000818	CcSEcCtD
Duloxetine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000143	0.000817	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000142	0.000811	CcSEcCtD
Duloxetine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000141	0.000808	CcSEcCtD
Duloxetine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000141	0.000808	CcSEcCtD
Duloxetine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000141	0.000805	CcSEcCtD
Duloxetine—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000802	CcSEcCtD
Duloxetine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00014	0.0008	CcSEcCtD
Duloxetine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.0008	CcSEcCtD
Duloxetine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00014	0.000799	CcSEcCtD
Duloxetine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000139	0.000797	CcSEcCtD
Duloxetine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000138	0.000791	CcSEcCtD
Duloxetine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000138	0.00079	CcSEcCtD
Duloxetine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000788	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000785	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000785	CcSEcCtD
Duloxetine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000137	0.000784	CcSEcCtD
Duloxetine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000137	0.000783	CcSEcCtD
Duloxetine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000137	0.000783	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000136	0.000782	CcSEcCtD
Duloxetine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000136	0.000777	CcSEcCtD
Duloxetine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000136	0.000777	CcSEcCtD
Duloxetine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000136	0.000777	CcSEcCtD
Duloxetine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000136	0.000777	CcSEcCtD
Duloxetine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000135	0.000776	CcSEcCtD
Duloxetine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000774	CcSEcCtD
Duloxetine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.00077	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000768	CcSEcCtD
Duloxetine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000134	0.000767	CcSEcCtD
Duloxetine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.000763	CcSEcCtD
Duloxetine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000133	0.000761	CcSEcCtD
Duloxetine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000761	CcSEcCtD
Duloxetine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000133	0.000759	CcSEcCtD
Duloxetine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000132	0.000756	CcSEcCtD
Duloxetine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.000755	CcSEcCtD
Duloxetine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000131	0.000753	CcSEcCtD
Duloxetine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000131	0.000752	CcSEcCtD
Duloxetine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.00075	CcSEcCtD
Duloxetine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.000749	CcSEcCtD
Duloxetine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000131	0.000749	CcSEcCtD
Duloxetine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000131	0.000748	CcSEcCtD
Duloxetine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00013	0.000746	CcSEcCtD
Duloxetine—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000746	CcSEcCtD
Duloxetine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00013	0.000745	CcSEcCtD
Duloxetine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00013	0.000743	CcSEcCtD
Duloxetine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00013	0.000743	CcSEcCtD
Duloxetine—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000743	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.000741	CcSEcCtD
Duloxetine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000129	0.00074	CcSEcCtD
Duloxetine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000734	CcSEcCtD
Duloxetine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.000734	CcSEcCtD
Duloxetine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000127	0.000728	CcSEcCtD
Duloxetine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000728	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000728	CcSEcCtD
Duloxetine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.000722	CcSEcCtD
Duloxetine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000126	0.000722	CcSEcCtD
Duloxetine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.000718	CcSEcCtD
Duloxetine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000125	0.000718	CcSEcCtD
Duloxetine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000125	0.000718	CcSEcCtD
Duloxetine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.000718	CcSEcCtD
Duloxetine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000125	0.000716	CcSEcCtD
Duloxetine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000125	0.000716	CcSEcCtD
Duloxetine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000124	0.00071	CcSEcCtD
Duloxetine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000124	0.000709	CcSEcCtD
Duloxetine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000124	0.000709	CcSEcCtD
Duloxetine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000707	CcSEcCtD
Duloxetine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000123	0.000707	CcSEcCtD
Duloxetine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000123	0.000705	CcSEcCtD
Duloxetine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000704	CcSEcCtD
Duloxetine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000123	0.000704	CcSEcCtD
Duloxetine—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000702	CcSEcCtD
Duloxetine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000122	0.000702	CcSEcCtD
Duloxetine—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000122	0.000696	CcSEcCtD
Duloxetine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000694	CcSEcCtD
Duloxetine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000693	CcSEcCtD
Duloxetine—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000689	CcSEcCtD
Duloxetine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.000682	CcSEcCtD
Duloxetine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.000678	CcSEcCtD
Duloxetine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.000678	CcSEcCtD
Duloxetine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000117	0.00067	CcSEcCtD
Duloxetine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000117	0.00067	CcSEcCtD
Duloxetine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000117	0.000669	CcSEcCtD
Duloxetine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000668	CcSEcCtD
Duloxetine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000114	0.000656	CcSEcCtD
Duloxetine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000114	0.000652	CcSEcCtD
Duloxetine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000114	0.000652	CcSEcCtD
Duloxetine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000112	0.000643	CcSEcCtD
Duloxetine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.000643	CcSEcCtD
Duloxetine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000642	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000642	CcSEcCtD
Duloxetine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000111	0.000639	CcSEcCtD
Duloxetine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00011	0.000632	CcSEcCtD
Duloxetine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00011	0.00063	CcSEcCtD
Duloxetine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000109	0.000622	CcSEcCtD
Duloxetine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000109	0.000622	CcSEcCtD
Duloxetine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000619	CcSEcCtD
Duloxetine—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000617	CcSEcCtD
Duloxetine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000107	0.000616	CcSEcCtD
Duloxetine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000613	CcSEcCtD
Duloxetine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000106	0.000609	CcSEcCtD
Duloxetine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000106	0.000607	CcSEcCtD
Duloxetine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000603	CcSEcCtD
Duloxetine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000105	0.000601	CcSEcCtD
Duloxetine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000105	0.000601	CcSEcCtD
Duloxetine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000103	0.000589	CcSEcCtD
Duloxetine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.000587	CcSEcCtD
Duloxetine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000579	CcSEcCtD
Duloxetine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.000578	CcSEcCtD
Duloxetine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000101	0.000578	CcSEcCtD
Duloxetine—Rash—Formoterol—chronic obstructive pulmonary disease	0.0001	0.000573	CcSEcCtD
Duloxetine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.0001	0.000573	CcSEcCtD
Duloxetine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	9.99e-05	0.000572	CcSEcCtD
Duloxetine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	9.99e-05	0.000572	CcSEcCtD
Duloxetine—Weight increased—Prednisone—chronic obstructive pulmonary disease	9.99e-05	0.000572	CcSEcCtD
Duloxetine—Headache—Formoterol—chronic obstructive pulmonary disease	9.94e-05	0.000569	CcSEcCtD
Duloxetine—Headache—Arformoterol—chronic obstructive pulmonary disease	9.94e-05	0.000569	CcSEcCtD
Duloxetine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.000569	CcSEcCtD
Duloxetine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	9.92e-05	0.000568	CcSEcCtD
Duloxetine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	9.9e-05	0.000567	CcSEcCtD
Duloxetine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	9.9e-05	0.000567	CcSEcCtD
Duloxetine—Vomiting—Montelukast—chronic obstructive pulmonary disease	9.88e-05	0.000566	CcSEcCtD
Duloxetine—Rash—Montelukast—chronic obstructive pulmonary disease	9.8e-05	0.000561	CcSEcCtD
Duloxetine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	9.79e-05	0.000561	CcSEcCtD
Duloxetine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	9.77e-05	0.00056	CcSEcCtD
Duloxetine—Headache—Montelukast—chronic obstructive pulmonary disease	9.73e-05	0.000558	CcSEcCtD
Duloxetine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	9.65e-05	0.000553	CcSEcCtD
Duloxetine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	9.62e-05	0.000551	CcSEcCtD
Duloxetine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	9.59e-05	0.00055	CcSEcCtD
Duloxetine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	9.52e-05	0.000546	CcSEcCtD
Duloxetine—Malaise—Prednisolone—chronic obstructive pulmonary disease	9.49e-05	0.000544	CcSEcCtD
Duloxetine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	9.46e-05	0.000542	CcSEcCtD
Duloxetine—Rash—Salbutamol—chronic obstructive pulmonary disease	9.44e-05	0.000541	CcSEcCtD
Duloxetine—Syncope—Prednisolone—chronic obstructive pulmonary disease	9.44e-05	0.000541	CcSEcCtD
Duloxetine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	9.43e-05	0.000541	CcSEcCtD
Duloxetine—Nausea—Arformoterol—chronic obstructive pulmonary disease	9.42e-05	0.00054	CcSEcCtD
Duloxetine—Nausea—Formoterol—chronic obstructive pulmonary disease	9.42e-05	0.00054	CcSEcCtD
Duloxetine—Headache—Salbutamol—chronic obstructive pulmonary disease	9.38e-05	0.000538	CcSEcCtD
Duloxetine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	9.25e-05	0.00053	CcSEcCtD
Duloxetine—Nausea—Montelukast—chronic obstructive pulmonary disease	9.23e-05	0.000529	CcSEcCtD
Duloxetine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	9.12e-05	0.000522	CcSEcCtD
Duloxetine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	9.09e-05	0.000521	CcSEcCtD
Duloxetine—Nausea—Salbutamol—chronic obstructive pulmonary disease	8.9e-05	0.00051	CcSEcCtD
Duloxetine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	8.85e-05	0.000507	CcSEcCtD
Duloxetine—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	8.83e-05	0.000506	CcSEcCtD
Duloxetine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	8.79e-05	0.000503	CcSEcCtD
Duloxetine—Hallucination—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000501	CcSEcCtD
Duloxetine—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	8.63e-05	0.000495	CcSEcCtD
Duloxetine—Oedema—Prednisolone—chronic obstructive pulmonary disease	8.59e-05	0.000492	CcSEcCtD
Duloxetine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	8.59e-05	0.000492	CcSEcCtD
Duloxetine—Shock—Prednisolone—chronic obstructive pulmonary disease	8.45e-05	0.000484	CcSEcCtD
Duloxetine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	8.38e-05	0.00048	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	8.3e-05	0.000476	CcSEcCtD
Duloxetine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	8.21e-05	0.00047	CcSEcCtD
Duloxetine—Flushing—Prednisone—chronic obstructive pulmonary disease	8.15e-05	0.000467	CcSEcCtD
Duloxetine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	7.97e-05	0.000457	CcSEcCtD
Duloxetine—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	7.94e-05	0.000455	CcSEcCtD
Duloxetine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	7.85e-05	0.00045	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	7.83e-05	0.00204	CbGpPWpGaD
Duloxetine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	7.77e-05	0.000445	CcSEcCtD
Duloxetine—Alopecia—Prednisone—chronic obstructive pulmonary disease	7.76e-05	0.000445	CcSEcCtD
Duloxetine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	7.71e-05	0.000442	CcSEcCtD
Duloxetine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	7.7e-05	0.000441	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	7.7e-05	0.002	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	7.65e-05	0.00199	CbGpPWpGaD
Duloxetine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	7.65e-05	0.000438	CcSEcCtD
Duloxetine—Erythema—Prednisone—chronic obstructive pulmonary disease	7.65e-05	0.000438	CcSEcCtD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.57e-05	0.00197	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	7.51e-05	0.00195	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	7.49e-05	0.00195	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	7.48e-05	0.00195	CbGpPWpGaD
Duloxetine—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	7.47e-05	0.00194	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	7.46e-05	0.00194	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	7.46e-05	0.00194	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	7.4e-05	0.00193	CbGpPWpGaD
Duloxetine—Pain—Prednisolone—chronic obstructive pulmonary disease	7.35e-05	0.000421	CcSEcCtD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.24e-05	0.00188	CbGpPWpGaD
Duloxetine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	7.21e-05	0.000413	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	7.11e-05	0.00185	CbGpPWpGaD
Duloxetine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	7.1e-05	0.000407	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	7.08e-05	0.000406	CcSEcCtD
Duloxetine—Anaemia—Prednisone—chronic obstructive pulmonary disease	7.07e-05	0.000405	CcSEcCtD
Duloxetine—Agitation—Prednisone—chronic obstructive pulmonary disease	7.03e-05	0.000403	CcSEcCtD
Duloxetine—Angioedema—Prednisone—chronic obstructive pulmonary disease	6.99e-05	0.0004	CcSEcCtD
Duloxetine—Malaise—Prednisone—chronic obstructive pulmonary disease	6.9e-05	0.000395	CcSEcCtD
Duloxetine—Vertigo—Prednisone—chronic obstructive pulmonary disease	6.87e-05	0.000394	CcSEcCtD
Duloxetine—Syncope—Prednisone—chronic obstructive pulmonary disease	6.86e-05	0.000393	CcSEcCtD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	6.85e-05	0.00178	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	6.85e-05	0.00178	CbGpPWpGaD
Duloxetine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	6.82e-05	0.000391	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	6.72e-05	0.00175	CbGpPWpGaD
Duloxetine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	6.72e-05	0.000385	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	6.71e-05	0.00175	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	6.71e-05	0.00175	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	6.67e-05	0.00174	CbGpPWpGaD
Duloxetine—Convulsion—Prednisone—chronic obstructive pulmonary disease	6.63e-05	0.00038	CcSEcCtD
Duloxetine—Hypertension—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.000378	CcSEcCtD
Duloxetine—HTR2C—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	6.52e-05	0.0017	CbGpPWpGaD
Duloxetine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000373	CcSEcCtD
Duloxetine—Myalgia—Prednisone—chronic obstructive pulmonary disease	6.51e-05	0.000373	CcSEcCtD
Duloxetine—Anxiety—Prednisone—chronic obstructive pulmonary disease	6.49e-05	0.000372	CcSEcCtD
Duloxetine—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	6.48e-05	0.00169	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	6.48e-05	0.00169	CbGpPWpGaD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	6.47e-05	0.00037	CcSEcCtD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	6.45e-05	0.00168	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	6.45e-05	0.00168	CbGpPWpGaD
Duloxetine—Discomfort—Prednisone—chronic obstructive pulmonary disease	6.43e-05	0.000369	CcSEcCtD
Duloxetine—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	6.39e-05	0.00166	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	6.39e-05	0.00166	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.37e-05	0.00166	CbGpPWpGaD
Duloxetine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	6.33e-05	0.000363	CcSEcCtD
Duloxetine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.3e-05	0.00164	CbGpPWpGaD
Duloxetine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	6.24e-05	0.000358	CcSEcCtD
Duloxetine—Oedema—Prednisone—chronic obstructive pulmonary disease	6.24e-05	0.000358	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.22e-05	0.00162	CbGpPWpGaD
Duloxetine—Infection—Prednisone—chronic obstructive pulmonary disease	6.2e-05	0.000355	CcSEcCtD
Duloxetine—Shock—Prednisone—chronic obstructive pulmonary disease	6.14e-05	0.000352	CcSEcCtD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.14e-05	0.0016	CbGpPWpGaD
Duloxetine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	6.12e-05	0.000351	CcSEcCtD
Duloxetine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	6.09e-05	0.000349	CcSEcCtD
Duloxetine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	6.06e-05	0.000347	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	6.03e-05	0.000346	CcSEcCtD
Duloxetine—Anorexia—Prednisone—chronic obstructive pulmonary disease	5.95e-05	0.000341	CcSEcCtD
Duloxetine—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	5.88e-05	0.00153	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.87e-05	0.00153	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	5.84e-05	0.00152	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	5.83e-05	0.00152	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.8e-05	0.00151	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	5.79e-05	0.00151	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.72e-05	0.00149	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	5.69e-05	0.000326	CcSEcCtD
Duloxetine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	5.68e-05	0.000325	CcSEcCtD
Duloxetine—Insomnia—Prednisone—chronic obstructive pulmonary disease	5.65e-05	0.000323	CcSEcCtD
Duloxetine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	5.61e-05	0.000321	CcSEcCtD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	5.6e-05	0.00146	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	5.53e-05	0.00144	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	5.5e-05	0.00143	CbGpPWpGaD
Duloxetine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.000315	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.48e-05	0.00142	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	5.46e-05	0.00142	CbGpPWpGaD
Duloxetine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	5.43e-05	0.000311	CcSEcCtD
Duloxetine—Rash—Prednisolone—chronic obstructive pulmonary disease	5.42e-05	0.00031	CcSEcCtD
Duloxetine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	5.41e-05	0.00031	CcSEcCtD
Duloxetine—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.4e-05	0.0014	CbGpPWpGaD
Duloxetine—Fatigue—Prednisone—chronic obstructive pulmonary disease	5.38e-05	0.000308	CcSEcCtD
Duloxetine—Headache—Prednisolone—chronic obstructive pulmonary disease	5.38e-05	0.000308	CcSEcCtD
Duloxetine—Constipation—Prednisone—chronic obstructive pulmonary disease	5.34e-05	0.000306	CcSEcCtD
Duloxetine—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.33e-05	0.00139	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.29e-05	0.00138	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	5.28e-05	0.00138	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.22e-05	0.00136	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	5.18e-05	0.00135	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.15e-05	0.00134	CbGpPWpGaD
Duloxetine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	5.14e-05	0.000295	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.11e-05	0.00133	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	5.1e-05	0.000292	CcSEcCtD
Duloxetine—Nausea—Prednisolone—chronic obstructive pulmonary disease	5.1e-05	0.000292	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.09e-05	0.00132	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	5.04e-05	0.00131	CbGpPWpGaD
Duloxetine—Urticaria—Prednisone—chronic obstructive pulmonary disease	4.96e-05	0.000284	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.94e-05	0.00129	CbGpPWpGaD
Duloxetine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	4.93e-05	0.000283	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	4.93e-05	0.000283	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	4.8e-05	0.00125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	4.77e-05	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	4.7e-05	0.00122	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.7e-05	0.00122	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	4.68e-05	0.00122	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.68e-05	0.00122	CbGpPWpGaD
Duloxetine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	4.6e-05	0.000263	CcSEcCtD
Duloxetine—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	4.54e-05	0.00118	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	4.53e-05	0.00118	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.52e-05	0.00118	CbGpPWpGaD
Duloxetine—Asthenia—Prednisone—chronic obstructive pulmonary disease	4.48e-05	0.000257	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.47e-05	0.00116	CbGpPWpGaD
Duloxetine—Pruritus—Prednisone—chronic obstructive pulmonary disease	4.42e-05	0.000253	CcSEcCtD
Duloxetine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.42e-05	0.00115	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	4.38e-05	0.00114	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.36e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.32e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.29e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.27e-05	0.00111	CbGpPWpGaD
Duloxetine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	4.27e-05	0.000245	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.23e-05	0.0011	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.21e-05	0.0011	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.2e-05	0.00109	CbGpPWpGaD
Duloxetine—Dizziness—Prednisone—chronic obstructive pulmonary disease	4.13e-05	0.000236	CcSEcCtD
Duloxetine—HTR2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	4.09e-05	0.00106	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.06e-05	0.00106	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	4.05e-05	0.00105	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	4.03e-05	0.00105	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.02e-05	0.00105	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	4.01e-05	0.00104	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4e-05	0.00104	CbGpPWpGaD
Duloxetine—Vomiting—Prednisone—chronic obstructive pulmonary disease	3.97e-05	0.000227	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	3.95e-05	0.00103	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	3.95e-05	0.00103	CbGpPWpGaD
Duloxetine—Rash—Prednisone—chronic obstructive pulmonary disease	3.94e-05	0.000225	CcSEcCtD
Duloxetine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	3.93e-05	0.000225	CcSEcCtD
Duloxetine—Headache—Prednisone—chronic obstructive pulmonary disease	3.91e-05	0.000224	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	3.88e-05	0.00101	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.85e-05	0.001	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.84e-05	0.000999	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.83e-05	0.000997	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.82e-05	0.000993	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.79e-05	0.000987	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.79e-05	0.000987	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.79e-05	0.000987	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.78e-05	0.000983	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.76e-05	0.000979	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	3.76e-05	0.000978	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	3.76e-05	0.000978	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.74e-05	0.000974	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.71e-05	0.000965	CbGpPWpGaD
Duloxetine—Nausea—Prednisone—chronic obstructive pulmonary disease	3.71e-05	0.000212	CcSEcCtD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.69e-05	0.00096	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.67e-05	0.000956	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.66e-05	0.000951	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.63e-05	0.000943	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.44e-05	0.000896	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.44e-05	0.000895	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.43e-05	0.000892	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.41e-05	0.000888	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.39e-05	0.000883	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.39e-05	0.000882	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.37e-05	0.000877	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.33e-05	0.000867	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.29e-05	0.000857	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.29e-05	0.000856	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	3.29e-05	0.000855	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.27e-05	0.00085	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.26e-05	0.000848	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.23e-05	0.000841	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.21e-05	0.000836	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.09e-05	0.000805	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	3.08e-05	0.000802	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.99e-05	0.000778	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.93e-05	0.000763	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.89e-05	0.000753	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.89e-05	0.000751	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	2.82e-05	0.000733	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.81e-05	0.000731	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.76e-05	0.000719	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.76e-05	0.000718	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.68e-05	0.000697	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.67e-05	0.000695	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.64e-05	0.000686	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	2.62e-05	0.000682	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.62e-05	0.000682	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.56e-05	0.000666	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.53e-05	0.000657	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.52e-05	0.000657	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.38e-05	0.000619	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.32e-05	0.000603	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.3e-05	0.000599	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.29e-05	0.000597	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	2.29e-05	0.000596	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.27e-05	0.000592	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.27e-05	0.00059	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.19e-05	0.00057	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.16e-05	0.000562	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.16e-05	0.000561	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.13e-05	0.000553	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.07e-05	0.000538	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.05e-05	0.000534	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.05e-05	0.000534	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.04e-05	0.00053	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.03e-05	0.000529	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.03e-05	0.000529	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.03e-05	0.000527	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.02e-05	0.000526	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.99e-05	0.000519	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.93e-05	0.000502	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.88e-05	0.000489	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.88e-05	0.000488	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.87e-05	0.000486	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.86e-05	0.000484	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.85e-05	0.000482	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.85e-05	0.00048	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.84e-05	0.00048	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.77e-05	0.00046	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.77e-05	0.000459	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.76e-05	0.000458	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.74e-05	0.000452	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.73e-05	0.000451	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.69e-05	0.00044	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.69e-05	0.00044	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.69e-05	0.000439	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.68e-05	0.000436	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.66e-05	0.000432	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.57e-05	0.000409	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.56e-05	0.000406	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.55e-05	0.000403	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.49e-05	0.000387	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.42e-05	0.000369	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.41e-05	0.000366	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.39e-05	0.000362	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.38e-05	0.00036	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.35e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.29e-05	0.000336	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.28e-05	0.000332	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.27e-05	0.000332	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.26e-05	0.000328	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.25e-05	0.000326	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.2e-05	0.000312	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.15e-05	0.000299	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.14e-05	0.000297	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.11e-05	0.000288	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.09e-05	0.000284	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.08e-05	0.00028	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.04e-05	0.000272	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.04e-05	0.00027	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.04e-05	0.000269	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.98e-06	0.00026	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.98e-06	0.00026	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.9e-06	0.000258	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.88e-06	0.000257	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.83e-06	0.000256	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.43e-06	0.000246	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.27e-06	0.000241	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.23e-06	0.00024	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	9.12e-06	0.000237	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.06e-06	0.000236	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.05e-06	0.000236	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9e-06	0.000234	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.51e-06	0.000221	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.37e-06	0.000218	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	8.33e-06	0.000217	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.05e-06	0.00021	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.96e-06	0.000207	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.63e-06	0.000198	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.57e-06	0.000197	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.55e-06	0.000197	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.45e-06	0.000194	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.28e-06	0.000189	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.95e-06	0.000181	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.94e-06	0.000181	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.8e-06	0.000177	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.62e-06	0.000172	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.58e-06	0.000171	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.4e-06	0.000166	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.32e-06	0.000164	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.31e-06	0.000164	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.24e-06	0.000162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.16e-06	0.00016	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.12e-06	0.000159	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.03e-06	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.88e-06	0.000153	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.86e-06	0.000153	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.57e-06	0.000145	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.57e-06	0.000145	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.35e-06	0.000139	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.14e-06	0.000134	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.09e-06	0.000132	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.01e-06	0.00013	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.84e-06	0.000126	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.7e-06	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.59e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.5e-06	0.000117	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.47e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.35e-06	0.000113	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.28e-06	0.000111	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.99e-06	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.91e-06	0.000102	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	3.79e-06	9.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.78e-06	9.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.62e-06	9.43e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.46e-06	9.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.28e-06	8.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.01e-06	7.82e-05	CbGpPWpGaD
